drugset / Trial / NCT03433807
Expanded Access Program for Idebenone in Participants With Duchenne Muscular Dystrophy (DMD)
Summary
The primary objective of this Expanded Access Program is to provide idebenone as a treatment for eligible participants with Duchenne Muscular Dystrophy before it is commercially available in the United States (U.S.) for the indication of DMD.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Idebenone | Small molecule | 900 mg | — |